Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other hematologic neoplasm 2Myeloid 2Gastrointestinal 2Plasma cell 1Other neoplasm 1Lymphoid 1Head & Neck 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1

Interventions

avatrombopag 5iron isomaltoside 1000 4hetrombopag 3ferric carboxymaltose 3Cytarabine 3eltrombopag 2Rivaroxaban 2Radiotherapy 2Meropenem 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Erythropoietin 2Cyclophosphamide 2Azacitidine 2thymoglobulin 1stinging nettle lectin 1romiplostim 1raltitrexed 1peppermint oil 1pegfilgrastim 1oprelvekin 1fludarabine phosphate 1fludarabine 1ferrous succinate 1ferrous fumarate 1ferric derisomaltose 1epoetin beta 1cc-486 1Vitamin B 12 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Amifostine × Classical hematology × Clear all
NCT00003827 2013-12-04

Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡